Dianthus Therapeutics Inc
NASDAQ:DNTH

Watchlist Manager
Dianthus Therapeutics Inc Logo
Dianthus Therapeutics Inc
NASDAQ:DNTH
Watchlist
Price: 44.1 USD 0.23% Market Closed
Market Cap: 1.9B USD

Net Margin

-4 104.8%
Current
Declining
by 2 074.3%
vs 3-y average of -2 030.5%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-4 104.8%
=
Net Income
$-126.3m
/
Revenue
$3.1m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-4 104.8%
=
Net Income
$-126.3m
/
Revenue
$3.1m

Peer Comparison

Country Company Market Cap Net
Margin
US
Dianthus Therapeutics Inc
NASDAQ:DNTH
1.9B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.4B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
No Stocks Found

Market Distribution

Lower than 96% of companies in the United States of America
Percentile
4th
Based on 12 771 companies
4th percentile
-4 104.8%
Low
-4 073 233.3% — -2.2%
Typical Range
-2.2% — 12.9%
High
12.9% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 073 233.3%
30th Percentile -2.2%
Median 5.2%
70th Percentile 12.9%
Max 1 135 400%

Dianthus Therapeutics Inc
Glance View

Market Cap
1.9B USD
Industry
Biotechnology

Dianthus Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts and currently employs 67 full-time employees. The company went IPO on 2018-06-21. Dianthus Therapeutics, Inc., formerly Magenta Therapeutics, Inc., is a clinical-stage biotechnology company engaged in designing and delivering monoclonal antibodies. The Company’s lead antibody, DNTH103, is engineered with an extended half-life, improved potency, and high selectivity for only the active C1s complement protein that drives disease pathology, enabling less frequent and more convenient self-administered subcutaneous injections. DNTH103 is an investigational, long-acting monoclonal antibody engineered to potently and selectively inhibit the active form of C1s, a clinically validated target in the classical complement pathway. As the classical pathway plays a significant role in disease pathology across a range of neuromuscular disorders, DNTH103 holds the potential to be a pipeline in a product beginning with generalized Myasthenia Gravis (gMG), Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy.

DNTH Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-4 104.8%
=
Net Income
$-126.3m
/
Revenue
$3.1m
What is Dianthus Therapeutics Inc's current Net Margin?

The current Net Margin for Dianthus Therapeutics Inc is -4 104.8%, which is below its 3-year median of -2 030.5%.

How has Net Margin changed over time?

Over the last 2 years, Dianthus Therapeutics Inc’s Net Margin has decreased from -3 756.6% to -4 104.8%. During this period, it reached a low of -4 104.8% on Oct 30, 2025 and a high of -760.1% on Mar 31, 2024.

Back to Top